Cargando…
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
BACKGROUND: Fibrates have been reported to cause paradoxical decreases in HDL-C in certain patients. DESIGN AND METHODS: This post-hoc analysis explored the frequency/magnitude of HDL-C reductions in a pooled database of mixed dyslipidemic patients (LDL-C:3.4-5.7 mmol/L;TG:1.7-5.7 mmol/L) receiving...
Autores principales: | Farnier, Michel, Dong, Qian, Shah, Arvind, Johnson-Levonas, Amy O, Brudi, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250955/ https://www.ncbi.nlm.nih.gov/pubmed/22087637 http://dx.doi.org/10.1186/1476-511X-10-212 |
Ejemplares similares
-
Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency
por: Viigimaa, Margus, et al.
Publicado: (2010) -
Ternary Eutectic Ezetimibe–Simvastatin–Fenofibrate
System and the Physical Stability of Its Amorphous Form
por: Knapik-Kowalczuk, Justyna, et al.
Publicado: (2021) -
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
por: Rotella, Carlo M, et al.
Publicado: (2010) -
Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia
por: Visseren, F. L. J.
Publicado: (2011) -
Rhabdomyolysis after ezetimibe/simvastatin therapy in an HIV-infected patient
por: Chanson, Noemie, et al.
Publicado: (2008)